Kidney involvement in monoclonal gammopathies: multidisciplinary approach in oncohematology and nephrology

The pathogenetic relationship of kidney damage and an aberrant clone of the B-cell line producing nephrotoxic monoclonal immunoglobulin underlies the concept of “monoclonal gammopathy of renal significance” (MGRS). Herein the aberrant clone does not reach the criteria necessary for initiating antitumor therapy according to oncohematological indications. MGRS is a new nosology in modern nephrology and oncohematology. Monoclonal protein’s pathological effects on kidney parenchyma result in irreversible decline of kidney function till the end stage renal disease that in line with the position of International Consensus of hematologists and nephrologists determinates critical necessity for clone specific treatment in patients with MGRS despite the absence of hematological indications for treatment initiation. Main challenge of MGRS in Russian Federation is an inaccessibility of an in-time diagnostic and appropriate treatment for the great majority of patients due to the following reasons: i) limited knowledge about the MGRS among hematologists and nephrologists; ii) lack of necessary diagnostic resources in most health-care facilities; iii) lack of approved clinical recommendations and medical economic standards for treatment of this pathological entity. In order to overcome these limitations, leading oncohematologists and nephrologists of the Russian Federation on behalf of professional communities at the end of 2019 published a conciliation document: “Monoclonal gammopathy of renal significance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment”. Consensus document comprises the opinion of experts – leading nephrologists and hematologists of Russian Federation – on the problem of MGRS including the incoherence in nosology classification, diagnostics approach and rationale for clone specific treatment. Consensus document is based on conclusions and agreements reached during the conference of leading nephrologists and hematologists of Russia which was held in the framework of symposia “Plasma cell dyscrasias and lymphoproliferative diseases: modern approaches to therapy”, 15–16 of March 2019, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia. Consensus is intended to define the principal practical steps to resolve the problem of MGRS in Russian Federation that are summarized as final clauses which we present here.

1. Dimopoulos M.A., Sonneveld P., Leung N. et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 2016;34(13):1544–57. DOI: 10.1200/JCO.2015.65.0044.

2. Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S. et al. National clinical recommendations on diagnosis and treatment of multiple myeloma. Gematologiya i transfusiologiya = Hematology and Transfusiology 2016;61(1, Suppl.2):1–24. (In Russ.). DOI: 10.18821/0234-5730-2016-61-1.

3. Merlini G., Stone M.J. Dangerous small B-cell clones. Blood 2006;108(8):2520–30. DOI: 10.1182/blood-2006-03-001164.

4. Leung N., Bridoux F., Hutchison C.A. et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120(22):4292–5. DOI: 10.1182/blood-2012-07-445304.

5. Leung N., Bridoux F., Batuman V. et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15(1):45–59. DOI: 10.1038/s41581-018-0077-4.

6. Rovin B.H., Caster D.J., Cattran D.C. et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019;(95):281–95. DOI: 10.1016/j.kint.2018.11.008.

7. Russian clinical recommendations on diagnostic and treatment of lymphoproliferative disorders, 2016. Eds.: I.V. Poddubnaya, B.G. Savchenko. Available at: http://www.hematology.ru/oncohematology/standarts/clinical_guidelines-draft.pdf. (In Russ.).

8. Zand L., Nasr S.H., Gertz M.A. et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma 2015;56(12):3357–64. DOI: 10.3109/10428194.2015.

9. Lin J., Markowitz G.S., Valeri A.M. et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12(7):1482–92. DOI: 10.4084/MJHID.2019.007.

10. Nasr S.H., Valeri A.M., Cornell L.D. et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012;7:231–9. DOI: 10.2215/CJN.08640811.

11. Nasr S.H., Valeri A.M., Cornell L.D. et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011;6:775–84. DOI: 10.2215/CJN.08300910.

12. Steiner N., Göbel G., Suchecki P. et al. Monoclonal gammopathy of renal significance(MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 2017;9(2):2344–56. DOI: 10.18632/oncotarget.23412.

13. Kourelis T.V., Nasr S.H., Dispenzieri A. et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 2016;91(11):1123–8. DOI: 10.1002/ajh.24528.

14. Cohen C., Royer B., Javaugue V. et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 2015;88:1135–43. DOI: 10.1038/ki.2015.201.

15. Ziogas D.C., Kastritis E., Terpos E. et al. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomibbased regimens. Leuk Lymphoma 2017;58(8):1832–9. DOI: 10.1080/10428194.2016.1267349.

16. Gumber R., Cohen J.B., Palmer M.B. et al. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 2018;94(1):199–205. DOI: 10.1016/j.kint.2018.02.020.

17. Kozlovskaya L.V., Rameev V.V., Kogarko I.N. et al. Renal lesions associated with monoclonal gammopathies of undetermined significance: clinical forms, mechanisms of development, approaches to treatment. Klinicheskaya meditsina = Clinical Medicine 2016;94(12):892–901. (In Russ.). DOI: 10.18821/0023-2149-2016-94-12892-901.

18. Khrabrova M.S., Dobronravov V.A., Smirnov A.V. Kidney disease associated with monoclonal gammopathies: singlecenter study. Nefrologiya = Nephrology 2018;22(6):38–46. (In Russ.). DOI: 10.24884/1561-6274-2018-22-6-38-46.

19. Zakharova E.V., Stolyarevich E.S. Kidney damage in lymphoproliferative and plasma cell disorders (one center experience). Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine 2014;(30):3–11.(In Russ.) DOI: 10.18786/20720505-2014-30-3-11.

20. Zakharova E.V., Makarova T.A., Stolyarevich E.S. et al. Monoclonal gammopathy of renal significance: a novel combination of C3 glomerulopathy and light-chain proximal tubulopathy. J Onco-Nephrol 2020. DOI: 10.1177/2399369320916467.

21. Smirnov A.V., Afanasyev B.V., Poddubnaya I.V. et al. Monoclonal gammopathy of renal significance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment. Nefrologiya = Nephrology 2019;23(6):9–28. (In Russ.). DOI: 10.36485/15616274-2019-23-6-9-28.

22. Fermand J.P., Bridoux F., Dispenzieri A. et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018;132(14):1478–85. DOI: 10.1182/blood-2018-04-839480.

23. Sethi S., Rajkumar S.V. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013;88(11):1284–93. DOI: 10.1016/j.mayocp.2013.08.002.

24. Zuo C., Zhu Y., Xu G. An update to the pathogenesis for monoclonal gammopathy of renal significance. Crit Rev Oncol Hematol 2020;149:102926. DOI: 10.1016/j.critrevonc.2020.102926.

25. Bridoux F., Leung N., Hutchison C.A. et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015;87(4):698–711. DOI: 10.1038/ki.2014.408.

26. Matsushita K., van der Velde M., Astor B.C. et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet 2010;375(9731):2073–81. DOI: 10.1016/S0140-6736(10)60674-5.

27. Smirnov A.V., Dobronravov V.A., Kayukov I.G. Сardiorenal continuum, pathogenetical grounds of preventive nephrology. Nefrologiya = Nephrology 2005;9(3):7–15. (In Russ.).

28. Kyle R.A., San-Miguel J.F., Mateos M.V., Rajkumar S.V. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2014;28(5):775–90. DOI: 10.1016/j.hoc.2014.06.005.

29. Clinical recommendations on investigation and treatment of patients with chronic lymphocytic leukemia(2014). Group of authors under the leadership of V.G. Savchenko, I.V. Poddubnaya. Available at: https://blood.ru/documents/clinical%20guidelines/26.%20klinicheskierekomendacii-2014-xll.pdf. (In Russ.).

30. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375–90. DOI: 10.1182/blood-2016-01-643569.

31. Gertz M.A. Waldenström macroglobulinemia: 2018 update on diagnosis, risk stratification, and management. Am J Hematol 2018;1–11. DOI: 10.1002/ajh.25292.

32. Sethi S., Rajkumar S.V., D’Agati V.D. The Complexity and heterogeneity of monoclonal immunoglobulinassociated renal diseases. J Am Soc Nephrol 2018;29(7):1810–23. DOI: 10.1681/ASN.2017121319.

33. Larsen C.P., Messias N.C., Walker P.D. et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015;88(4):867–73. DOI: 10.1038/ki.2015.195.

34. Nasr S.H., Fidler M.E., Said S.M. Paraffin immunofluorescence: a valuable ancillary technique in renal pathology. Kidney Int Rep 2018;3(6):1260–6. DOI: 10.1016/j.ekir.2018.07.008.

35. Messias N.C., Walker P.D., Larsen C.P. et al. Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. Mod Pathol 2015;28(6):854–60. DOI: 10.1038/modpathol.2015.1.

36. Alexander M.P., Dasari S., Vrana J.A et al. Congophilic fibrillary glomerulonephritis: a case series. Am J Kidney Dis 2018;72(3): 325–36. DOI: 10.1053/j.ajkd.2018.03.017.

37. Nasr S.H., Vrana J.A., Dasari S. et al. DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep 2017;3(1):56–64. DOI: 10.1016/j.ekir.2017.07.017.

38. Herrera G.A., Sanders P.W., Reddy B.V. Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases. Ultrastruct Pathol 1994;18:401–16. DOI: 10.3109/01913129409023211

39. Gu X., Herrera G.A. Light-chainmediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006;130(2):165–9. DOI: 10.1043/1543-2165(2006)130[165:LATINA]2.0.CO;2.

40. Royal V., Quint P., Leblanc M. et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol 2015;26(4):784–90. DOI: 10.1681/ASN.2014050481.

41. Leung N., Barnidge D.R., Hutchison C.A. et al. Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Clin Chem Lab Med 2016;54(6):929–37. DOI: 10.1515/cclm-2015-0994.

42. Buxbaum J.N., Hurley M.E., Chuba J., Spiro T. Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med 1979;67(5):867–78. DOI: 10.1016/0002-9343(79)90747-2.

43. Benson M.D. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheum 1986;29(5):683–7. DOI: 10.1002/art.1780290515.

44. Vaxman I., Gertz M. Recent advances in the diagnosis, risk stratification, and management of systemic lightchain amyloidosis. Acta Haematol 2019;141(2):93–106. DOI: 10.1159/000495455.

45. Zakharova E.V., Stolyarevich E.S. Chemotherapy for renal AL amyloidosis: treatment results and outcomes in 49 patients from a single center. Clin Practic 2016;13(1):11–8.

46. Cohen O.C., Wechalekar A.D. Systemic amyloidosis: moving into the spotlight. Leukemia 2020;34(5):1215–28. DOI: 10.1038/s41375-020-0802-4.

47. Gertz M.A. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol 2020. DOI: 10.1002/ajh.25819.

48. Fermand J.P., Bridoux F., Kyle R.A. et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122(22):3583–90. DOI: 10.1182/blood-2013-05-495929.

49. Heilman R.L., Velosa J.A., Holley K.E. et al. Long-term follow-up and response to chemotherapy in patients with lightchain deposition disease. Am J Kidney Dis 1992;20(1):34–41. DOI: 10.1016/s0272-6386(12)80314-3.

50. Gavriatopoulou M., Musto P., Caers J. et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018;32(9):1883–98. DOI: 10.1038/s41375-018-0209-7.

51. Rosner M.H., Edeani A., Yanagita M. et al. Paraprotein–related kidney disease: diagnosing and treating monoclonal gammopathy of renal significance. Clin J Am Soc Nephrol 2016;11(12):2280–7. DOI: 10.2215/CJN.02920316.

52. Gertz M.A. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91(9):947–56. DOI: 10.1002/ajh.24433.

53. Lorenz E.C., Gertz M.A., Fervenza F.C. et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008;23(6):2052–7. DOI: 10.1093/ndt/gfm918.

54. Yu X.J., Zhang X., Li D.Y. et al. Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: a large retrospective case series study from a single institute in China. Nephrology (Carlton) 2020;25(3):202–11. DOI: 10.1111/nep.13633.

55. Huang J., Sun C., Su H. et al. Bortezomibbased chemotherapy with autologous stem cell transplantation for monoclonal gammopathy of renal significance: a case report and literature review. Kidney Blood Press Res 2019;44(4):858–69. DOI: 10.1159/000501314.

56. Pasquali S., Iannuzzella F., Corrandini M. et al. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 2015;28(2):251–4. DOI: 10.1007/s40620-014-0130-8.

57. Pendón-Ruiz de Mier M.V., Alvarez-Lara M.A. et al. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Nefrologia 2013;33(6):788–96. DOI: 10.3265/Nefrologia.pre2013. Sep.12176.

58. Mene P., Giammarioli E., Fofi C. et al. Serum free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res 2018;43(4):1263–72. DOI: 10.1159/000492408.

59. Decourt A., Gondouin B., Delaroziere J.C. et al. Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis. Clin J Am Soc Nephrol 2016;11(3):431–41. DOI: 10.2215/CJN.06290615.

60. Abudayyeh A.A., Lahoti A., Salahudeen A.K. et al. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 2014;85(5):1002–4. DOI: 10.1038/ki.2014.29.

61. Cohen E.P., Krzesinski J.M., LaunayVacher V., Sprangers B. Onco-nephrology: Core Curriculum 2015. Am J Kidney Dis 2015;66(5):869–83. DOI: 10.1053/j.ajkd.2015.04.042.

62. Cosmai L., Porta C., Perazella M.A. et al. Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant 2018;33(9):1503–10. DOI: 10.1093/ndt/gfy188.

63. Capasso A., Benigni A., Capitanio U. et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int 2019;96(3):555–67. DOI: 10.1016/j.kint.2019.04.043.